May 2nd 2025
Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid tumors.
March 10th 2025
March 7th 2025
March 6th 2025
March 5th 2025
March 31st 2025
March 3rd 2025
February 23rd 2025